Cited 43 times in
Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정현철 | - |
dc.date.accessioned | 2018-08-28T17:05:12Z | - |
dc.date.available | 2018-08-28T17:05:12Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 1347-9032 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/162239 | - |
dc.description.abstract | KEYNOTE-012 was a phase Ib, multicohort study designed to investigate efficacy and safety of pembrolizumab in advanced solid tumors. Results from the subset of patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) from the Asia-Pacific region are reported. Patients with recurrent/metastatic HNSCC, measurable disease (RECIST version 1.1), and ECOG performance status (PS) 0-1 were eligible for enrollment in the HNSCC expansion cohort. Patients received pembrolizumab 200 mg every 3 weeks. Response was assessed every 8 weeks. Co-primary end-points were safety and overall response rate (RECIST version 1.1, central review). Secondary end-points included overall survival and response duration. Patients enrolled at any of the five centers throughout the Asia-Pacific region were included in these analyses. Twenty-six patients with HNSCC from the Asia-Pacific region received pembrolizumab. The median age was 62 years, 65% of patients had ECOG PS 1, and 62% had received two or more prior therapies for recurrent/metastatic disease. Sixteen (62%) patients experienced a treatment-related adverse event of any grade, including two (8%) patients who experienced one or more events of grade 3 severity. No treatment-related deaths occurred. The overall response rate was 19% (95% confidence interval, 7%-39%). After a median follow-up of 12 months (range, 2-21 months), a median response duration was not reached (range, 6 to 17+ months); four of five responses lasted >/=6 months. Median overall survival was 11.6 months (95% confidence interval, 4.7-17.7 months). Pembrolizumab was well tolerated and had durable antitumor activity in patients with HNSCC from the Asia-Pacific region. (Trial registration no. NCT01848834.). | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Wiley Publishing on behalf of the Japanese Cancer Association | - |
dc.relation.isPartOf | CANCER SCIENCE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Monoclonal Antibodies, Humanized/*administration & dosage/therapeutic use | - |
dc.subject.MESH | Immunological/*administration & dosage/therapeutic use Antineoplastic Agents | - |
dc.subject.MESH | Asia | - |
dc.subject.MESH | Squamous Cell/*drug therapy Carcinoma | - |
dc.subject.MESH | Cohort Studies | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Head and Neck Neoplasms/*drug therapy | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Survival Analysis | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012 | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Makoto Tahara | - |
dc.contributor.googleauthor | Kei Muro | - |
dc.contributor.googleauthor | Yasuhisa Hasegawa | - |
dc.contributor.googleauthor | Hyun Cheol Chung | - |
dc.contributor.googleauthor | Chia-Chi Lin | - |
dc.contributor.googleauthor | Bhumsuk Keam | - |
dc.contributor.googleauthor | Kenichi Takahashi | - |
dc.contributor.googleauthor | Jonathan D Cheng | - |
dc.contributor.googleauthor | Yung-Jue Bang | - |
dc.identifier.doi | 10.1111/cas.13480 | - |
dc.contributor.localId | A03773 | - |
dc.relation.journalcode | J00454 | - |
dc.identifier.eissn | 1349-7006 | - |
dc.identifier.pmid | 29284202 | - |
dc.subject.keyword | Asia-Pacific | - |
dc.subject.keyword | PD-1 | - |
dc.subject.keyword | PD-L1 | - |
dc.subject.keyword | Pembrolizumab | - |
dc.subject.keyword | head and neck squamous cell carcinoma | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.citation.volume | 109 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 771 | - |
dc.citation.endPage | 776 | - |
dc.identifier.bibliographicCitation | CANCER SCIENCE, Vol.109(3) : 771-776, 2018 | - |
dc.identifier.rimsid | 59825 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.